TMPRSS2-ERG gene fusion in prostate cancer
Language English Country Czech Republic Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
25485532
DOI
10.5507/bp.2014.065
Knihovny.cz E-resources
- MeSH
- Gene Fusion genetics MeSH
- Oncogene Proteins, Fusion genetics MeSH
- Humans MeSH
- Biomarkers, Tumor MeSH
- Prostatic Neoplasms diagnosis genetics MeSH
- Prognosis MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Oncogene Proteins, Fusion MeSH
- Biomarkers, Tumor MeSH
- TMPRSS2-ERG fusion protein, human MeSH Browser
BACKGROUND: The TMPRSS2-ERG gene fusion is one of the most widely spread chromosomal rearrangements in carcinomas. Since its discovery, a number of studies have examined its diagnostic, prognostic and therapeutic implications for prostate cancer where suitable biomarkers are still lacking. The publication data are inconsistent. The aim of this review was to critically evaluate the current clinical impact of this gene fusion. METHODS: The PubMed online database was used to search relevant reviews and original articles. RESULTS: Although the TMPRSS2-ERG gene fusion appears to be a suitable diagnostic biomarker, the prognostic implications of this gene fusion are still unclear. Several new strategies for therapeutically targeting ETS fusions and their modulators have been identified and are currently being investigated. CONCLUSION: Due to the heterogeneity of prostate cancer, the combination of several biomarkers is necessary to accurately assess the presence of prostate cancer, predict its potential clinical outcome and decide on appropriate therapy (e.g. PARP inhibitors).
References provided by Crossref.org
